China’s biopharmaceutical sector is said to have entered an “innovation 2.0” phase as it moves to a commercialisation mindset that could see it sideline global competitors and outpace the US – despite restrictive trade policies.
In recent years, innovative drug development in the world’s second-largest pharmaceutical market has rapidly approached – and in some cases surpassed – that of the United States, the world’s biggest market.
Growing concerns over China’s biotech capabilities have led the…
China’s biopharma sector ‘in prime position to challenge US leadership’
